Clinical Trial Update: Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer [NA]

View source ↗

Summary

This completed clinical trial evaluated how frequently zoledronic acid should be given to prevent further bone loss in osteoporosis patients undergoing androgen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Zoledronic acid (Reclast) (zoledronic acid)

Snippet

Sponsor: Wirral University Teaching Hospital NHS Trust | Conditions: Osteoporosis | NA | Status: COMPLETED